Zanamivir hydrate(5:1)

Cat. No.: HY-13210A: Data Sheet Handling Instructions
FAQs
Technical Support

Zanamivir hydrate (5:1) is the hydrate of Zanamivir. Zanamivir is an influenza viral neuraminidase inhibitor with IC₅₀ values of 0.95 nM and 2.7 nM for influenza A and B, respectively.

For research use only. We do not sell to patients.

CAS No. : 171094-50-1

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Zanamivir hydrate(5:1):

Zanamivir

Other Forms of Zanamivir hydrate(5:1):

Zanamivir In-stock

16 Publications Citing Use of MCE Zanamivir hydrate(5:1)

RT-PCR

Cell Proliferation/Viability Assay

Microbiological Assay

: Zanamivir hydrate(5:1) purchased from MedChemExpress. Usage Cited in: Emerg Microbes Infect. 2025 Dec;14(1):2564308. [Abstract]; Compound susceptibility profiles of Zanamivir was assessed using a viral yield reduction assay in MDCK cells. Cells were infected with IDV and IAV (MOI = 0.1), followed by removal of the virus inoculum and treatment with serially diluted compounds. Supernatants were collected at designated timepoints post-infection for TCID₅₀ titration. Antiviral activity (%) was calculated relative to virus-free and drug-free controls.

: Zanamivir hydrate(5:1) purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2024 Feb 14;20(2):e1011981. [Abstract]; Western blotting analysis of LAMP1 and LAMP2 deglycosylation and degradation in HeLa cells transfected with plasmid expressing HN protein and treated with Peramivir (30 μg/mL) or Zanamivir (20 μg/mL; 24-48 h) at the indicated time points post-transfection. The results demonstrated that treatment with either Peramivir or Zanamivir significantly inhibited the deglycosylation and degradation of LAMP1 and LAMP2 following the transfection of the HN protein.

: Zanamivir hydrate(5:1) purchased from MedChemExpress. Usage Cited in: Viruses. 2024 Sep 14;16(9):1467.; Inhibitory effect of baloxavir in combination with NAIs in cells infected with H1N1-PR8-I38T mutant strain. The antiviral activity of baloxavir + NAIs was evaluated against H1N1-PR8-I38T in MDCK cells. Graphs showing the antiviral activity of baloxavir in combination with Zanamivir (3 days).

: Zanamivir hydrate(5:1) purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2021 Apr 24;6(1):165. [Abstract]; The preliminary in vitro antiviral activities of oseltamivir at 3 μM, Zanamivir (51 h) at 3 μM, baricitinib at 3.2 μM, olaparib at 3.2 μM, arbidol at 3 μM and 30 μM, and CVL218 at 3 μM and 30 μM, respectively, were detected in Vero E6 cells infected with SARS-CoV-2 at an MOI of 0.05. The viral yield in the cell supernatant was then quantified by qRT-PCR.

: Zanamivir hydrate(5:1) purchased from MedChemExpress. Usage Cited in: Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00222-20. [Abstract]; Synergetic antiviral effect of compounds 4a in combination with Zanamivir in cells infected with drug-resistant influenza virus. MDCK cells were infected with the ZX/1109 strain in the presence of the indicated concentrations of Zanamivir, and cell viability was evaluated at 3 days postinfection. The synergetic effects of compound 4a and Zanamivir were analyzed by MacSynergy II and shown in a three-dimensional plot. The volumes above and below the planes represent synergy and antagonism, respectively.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description	Zanamivir hydrate (5:1) is the hydrate of Zanamivir. Zanamivir is an influenza viral neuraminidase inhibitor with IC₅₀ values of 0.95 nM and 2.7 nM for influenza A and B, respectively^[1].
IC₅₀ & Target	IC₅₀: 0.95 nM (Influenza A); 2.7 nM (Influenza B)^[1]
In Vivo	Zanamivir has a poor bioavailability in oral administration, with only 4-17% of the agent. Oral delivery of Zanamivir has been a problem due to its strong hydrophilic nature that limits its transport across the intestinal epithelium. Permeation enhancers such as sodium cholate, hydroxypropyl β-cyclodextrin could be used with zanamivir to enhance the intestinal permeability^[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight	335.91
Formula	C₁₂H_20.4N₄O_7.2
CAS No.	171094-50-1
SMILES	NC(N[C@@H]1[C@H]([C@@]([H])(OC(C(O)=O)=C1)[C@@H]([C@@H](CO)O)O)NC(C)=O)=N.[0.2 H2O]
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (281 KB) Handling Instructions (2659 KB)
References	[1]. Gubareva LV, et al. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates ofinfluenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother. 2001 Dec;45(12):3403-8. [Content Brief] [2]. McKimm-Breschkin JL, et al. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med. 2005;4(2):107-16. [Content Brief] [3]. Shanmugam S, et al. Zanamivir oral delivery: enhanced plasma and lung bioavailability in rats. Biomol Ther (Seoul). 2013 Mar;21(2):161-9. [Content Brief]